• Fri, January 31, 2025

by: MoneyWeek

Is now a good time to invest in infrastructure?

While high interest rates have been a headwind for infrastructure stocks and trusts in recent years, the picture could be improving, as the UK government unveils plans to boost infrastructure investment.

by: WOPRAI

Short squeeze is starting in shares of MYSZ at $1.95, after crossing above the $1.949 Trigger Price

by: Investopedia

Top Stock Movers Now: Apple, AbbVie, Deckers Outdoor, and More

U.S. equities were mostly higher at midday on positive tech earnings news and a report showing December inflation came in as expected.

by: Kiplinger

Stock Market Today: Trump Tariff Worries Pressure Stocks

Stocks swung lower Friday after the White House confirmed it will impose tariffs on Mexico, Canada and China beginning tomorrow.

by: MSN

Invest $50,000 in This Stock and Get $2,950 Back Per Year in Dividends

First National Financial (TSX:FN) stock throws off a lot of income. The post Invest $50,000 in This Stock and Get $2,950 Back Per Year in Dividends appeared first on The Motley Fool Canada.

by: MSN

Meet the Canadian Stock That Continues to Crush the Market

It's normal to beat the market once or twice while riding a trend. But this stock has been crushing the market for years. The post Meet the Canadian Stock That Continues to Crush the Market appeared first on The Motley Fool Canada.

by: WOPRAI

Short squeeze is starting in shares of RGBPP at $0.09, after crossing above the $0.072 Trigger Price

by: Kiplinger

Intel Earnings Do Little to Excite Investors: What to Know

Intel stock is struggling for direction Friday after the chipmaker reported a fourth-quarter beat but gave weak guidance. Here's what Wall Street has to say.

by: WOPRAI

Short squeeze is starting in shares of NMFC at $11.665, after crossing above the $11.656 Trigger Price

by: MSN

Shopify stock soars to 52-week high of $120.81

Shopify Inc (NYSE:SHOP). shares have surged to a 52-week high, reaching a price level of $120.81, as the e-commerce platform continues to capitalize on the expanding online retail market. With a market capitalization of $154 billion and impressive revenue growth of 23.

by: MSN

3 Monthly Dividend Stocks to Buy and Hold Forever

Here are three of the best monthly dividend stocks you can buy on the TSX today. The post 3 Monthly Dividend Stocks to Buy and Hold Forever appeared first on The Motley Fool Canada.

by: WOPRAI

Short squeeze is starting in shares of NBY at $0.673, after crossing above the $0.662 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of HLGN at $1.06, after crossing above the $1.057 Trigger Price

by: MSN

How much money a $1,000 investment in Apple 10 years ago would be worth today

To give you a sense of the stock's value, CNBC calculated how much a $1,000 investment in Apple made one, five, 10 and 44 years ago — when the company went public in 1980 — would be worth today. CNBC's calculations below include total returns and are based on Apple's Jan.

by: MSN

Maze Therapeutics IPO opens trading modestly higher

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares starting to trade at $16.12. The company priced 8,750,000 shares of its common stock at a public offering price of $16.

by: WOPRAI

Short squeeze is starting in shares of PDFS at $27.73, after crossing above the $27.628 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of PCLB at $29.96, after crossing above the $29.15 Trigger Price

by: MSN

Is It Worth Investing in AST SpaceMobile (ASTS) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price,

by: WOPRAI

Short squeeze is starting in shares of LENZ at $26.9, after crossing above the $26.843 Trigger Price

by: MSN

Is It Worth Investing in Dell Technologies (DELL) Based on Wall Street's Bullish Views?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

by: WOPRAI

Short squeeze is starting in shares of CSPI at $19.84, after crossing above the $18.842 Trigger Price

by: MSN

AbbVie stock rises on solid annual profit guidance, Q4 beat

AbbVie (NYSE:ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the fiscal 2025 year exceeded analyst expectations, driven by strong sales in immunology drugs Skyrizi and Rinvoq.

by: WOPRAI

Short squeeze is starting in shares of RGEN at $169.78, after crossing above the $169.195 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of OCUL at $7.97, after crossing above the $7.831 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of BCRX at $7.945, after crossing above the $7.908 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CHGCF at $46.01, after crossing above the $44.115 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of GSAT at $1.585, after crossing above the $1.576 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of GRLRF at $0.71, after crossing above the $0.648 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of TMQ at $1.28, after crossing above the $1.272 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of STKL at $7.54, after crossing above the $7.502 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of VYNE at $2.439, after crossing above the $2.41 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of VIV at $8.87, after crossing above the $8.789 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of VIAV at $12.49, after crossing above the $12.273 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of TREX at $74.325, after crossing above the $74.291 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SPND at $2.49, after crossing above the $2.464 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SIGI at $83.44, after crossing above the $83.112 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of SETO at $0.037, after crossing above the $0.028 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of PMNT at $1.1, after crossing above the $1.078 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of MKSI at $116.09, after crossing above the $113.422 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of MAPSW at $0.09, after crossing above the $0.073 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of HUIZ at $3.5, after crossing above the $3.483 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of DPG at $11.834, after crossing above the $11.831 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CZNC at $21.57, after crossing above the $21.452 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of CMTV at $17.99, after crossing above the $17.641 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of ASCUF at $1.154, after crossing above the $1.145 Trigger Price

by: WOPRAI

Short squeeze is starting in shares of AP at $2.61, after crossing above the $2.581 Trigger Price

  • Sat, February 1, 2025

by: MSN

Want $3,000 in Annual Dividends? Invest $17,000 in Each of These 3 High-Yielding Stocks

Collecting dividends on a regular basis is an excellent way to give you some extra savings and strengthen your financial position. There are many dividend stocks to choose from, but finding ones that offer high yields and are safe can be challenging.

by: MSN

Should You Buy W.P. Carey While It's Below $60?

Investors looking at W.P. Carey (NYSE: WPC) will probably be enticed by its lofty 6.3% dividend yield. That's well above the S&P 500 index's 1.2% and the 3.8% yield of the average real estate investment trust (REIT).

AbbVie stock rises on solid annual profit guidance, Q4 beat

AbbVie (NYSE:ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the fiscal 2025 year exceeded analyst expectations, driven by strong sales in immunology drugs Skyrizi and Rinvoq.
AbbVie Inc. experienced a rise in its stock price following the announcement of its solid annual profit guidance and a better-than-expected fourth-quarter performance. The company reported adjusted earnings of $2.79 per share, surpassing the consensus estimate of $2.76 per share, although its revenue of $14.3 billion fell short of the expected $14.5 billion. Despite the revenue miss, AbbVie's 2024 earnings per share guidance was set at $11.05 to $11.25, which was above the Wall Street consensus of $11.19. This optimistic outlook was driven by strong sales from its immunology drugs, particularly Skyrizi and Rinvoq, which are expected to offset the declining sales of Humira due to biosimilar competition. Additionally, AbbVie's CEO, Richard Gonzalez, highlighted the company's strategic focus on growth through its diversified portfolio and new product launches.

Read the Full MSN Article at:
https://www.msn.com/en-ca/money/top-stocks/abbvie-stock-rises-on-solid-annual-profit-guidance-q4-beat/ar-AA1ybFH9